Syndax Pharmaceuticals SNDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $64.86M+224% | $68.73M+795% | $45.87M+267% | $37.96M+985% | $20.04M— | ||
| $58.85M-4.5% | $78.64M+20.0% | $56.28M-20.7% | $62.23M+27.9% | $61.64M+9.1% | ||
| —— | $44.92M+48.6% | $44.92M+48.6% | $44.92M+48.6% | $44.92M+48.6% | ||
| $37.59M-8.4% | —— | $44.92M+44.4% | $43.81M+50.7% | $41.03M+78.2% | ||
| $99.07M-4.6% | $131.28M+26.2% | $103.3M+1.2% | $107.31M+38.1% | $103.8M+30.5% | ||
| -$34.2M+59.2% | -$62.55M+35.1% | -$57.43M+35.9% | -$69.35M+6.6% | -$83.76M-5.3% | ||
| -52.7%+365pp | -91%+1,164pp | -125.2%+591pp | -182.7%+1,938pp | -417.9%— | ||
| $0-100% | $0+100% | $0-100% | $4K-91.1% | $2K-96.4% | ||
| -$8.47M-678% | -$5.47M-349% | -$3.29M-160% | -$2.49M-141% | -$1.09M-115% | ||
| $0— | —— | $0— | $0— | $0— | ||
| -$42.67M+49.7% | -$68.01M+27.8% | -$60.72M+27.8% | -$71.85M-5.6% | -$84.85M-17.2% | ||
| -65.8%+358pp | -99%+1,127pp | -132.4%+541pp | -189.3%+1,755pp | -423.3%— | ||
| -$0.48+51.0% | -$0.78+28.4% | -$0.70+28.6% | -$0.83-3.7% | -$0.98-15.3% | ||
| -$30.2M+63.9% | —— | —— | —— | -$83.76M— | ||
| -46.6%+371pp | —— | —— | —— | -417.9%— | ||
| -$34.2M+59.2% | -$62.55M+35.1% | -$57.43M+35.9% | -$69.35M+6.6% | -$83.76M-5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Syndax Pharmaceuticals's revenue?
- Syndax Pharmaceuticals (SNDX) generated $217.4M in revenue over the trailing twelve months, up 397.3% year over year.
- Is Syndax Pharmaceuticals profitable?
- Syndax Pharmaceuticals is not currently profitable: it reported a net loss of $243.2M over the trailing twelve months, a -111.9% net margin.
- What is Syndax Pharmaceuticals's earnings per share?
- Syndax Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.79.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
